Background: Multiple treatments are available for metastatic castration-resistant prostate cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and abiraterone, but therapy resistance remains a major clinical obstacle. We examined the clinical utility of low-pass whole-genome sequencing (LPWGS) of circulating tumor DNA (ctDNA) for prognostication in mCRPC.
Methods: A total of 200 plasma samples from 143 mCRPC patients collected at the start of first-line ARSI treatment (baseline) and at treatment termination (n = 57, matched) were analyzed by LPWGS (median: 0.50X) to access ctDNA% and copy number alteration (CNA) patterns. The best confirmed prostate specific antigen (PSA) response (≥50% decline [PSA50]), PSA progression-free survival (PFS), and overall survival (OS) were used as endpoints. For external validation, we used plasma LPWGS data from an independent cohort of 70 mCRPC patients receiving first-line ARSI.
Results: Baseline ctDNA% ranged from ≤3.0% to 73% (median: 6.6%) and CNA burden from 0% to 82% (median: 13.1%) in the discovery cohort. High ctDNA% and high CNA burden at baseline was associated with poor PSA50 response (P = 0.0123/0.0081), poor PFS (P < 0.0001), and poor OS (P < 0.0001). ctDNA% and CNA burden was higher at PSA progression than at baseline in 32.7% and 42.3% of the patients. High ctDNA% and high CNA burden at baseline was also associated with poor PFS and OS (P ≤ 0.0272) in the validation cohort.
Conclusions: LPWGS of ctDNA provides clinically relevant information about the tumor genome in mCRPC patients. Using LPWGS data, we show that high ctDNA% and CNA burden at baseline is associated with short PFS and OS in 2 independent cohorts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/clinchem/hvac224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Community-Engaged, Mixed-Methods Approach to Prioritizing Needs in a Statewide Assessment of Community Cancer Needs.
Prev Chronic Dis
December 2024
Community Impact Office, Markey Cancer Center, University of Kentucky, Lexington.
Introduction: Kentucky has the highest all-site cancer incidence and death rate in the US. In 2021, the University of Kentucky Markey Cancer Center convened a steering committee to conduct a statewide community cancer needs assessment (CNA). The goal of the final CNA phase was to gather community input on prioritizing Kentucky's cancer-related needs and ways to address them.
View Article and Find Full Text PDFGraph theoretic visualization of patient and health worker messaging in the EHR.
Front Artif Intell
December 2024
Switchboard MD, Inc., Atlanta, GA, United States.
Introduction: The electronic health record (EHR) has greatly expanded healthcare communication between patients and health workers. However, the volume and complexity of EHR messages have increased health workers' cognitive load, impeding effective care delivery and contributing to burnout.
Methods: To understand these potential detriments resulting from EHR communication, we analyzed EHR messages sent between patients and health workers at Emory Healthcare, a large academic healthcare system in Atlanta, Georgia.
Genomic differences of patients with hematologic malignancies in different age groups.
Commun Biol
December 2024
Department of Hematology, Peking University First Hospital, Beijing, China.
Article Synopsis
- Hematologic malignancies significantly impact the health of children, young adults, and older adults, yet their biological causes are not well understood.
- A study revealed notable differences in clinical features and genomic mutations between children/young adults (CYAs) and older adults (OAs) in these diseases, including lower mutational burdens in CYAs for many key genes.
- The research identified specific genes with varying mutation rates and emphasized the need for age-oriented personalized treatment options based on the distinct genetic and clinical landscapes of CYAs and OAs.
Non-invasive multi-cancer detection using DNA hypomethylation of LINE-1 retrotransposons.
Clin Cancer Res
December 2024
Irset, Rennes, France.
Purpose: The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge.
Experimental Design: We implemented a new highly sensitive strategy to detect base-pair resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of LINE-1 retrotransposons as a non-invasive multi-cancer detection biomarker.
Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation.
BMC Microbiol
November 2024
Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt.
Article Synopsis
- The increasing issue of multidrug resistance (MDR) in pathogenic bacteria like Staphylococcus aureus has prompted the search for new treatment methods, including FDA-drug repurposing.
- Ambroxol was tested against clinical MDR S. aureus isolates and showed effective antibacterial activity, with concentrations needed to inhibit growth between 0.75 to 1.5 mg/mL, and also disrupted biofilm formation in about 42% of the isolates.
- In vivo studies demonstrated ambroxol's ability to enhance skin tissue healing in S. aureus infected burn injuries by reducing bacterial presence and inflammation, with further investigations suggesting its action may involve binding to several targets in the bacterium.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!